SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on February 6, 2003; DOI 10.1182/blood-2002-04-1250. This Article Full Text (PDF) All Versions of this Article: 2002-04-1250v1 101/12/4930    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Hansson, L. Articles by Mellstedt, H. Search for Related Content PubMed PubMed Citation Articles by Hansson, L. Articles by Mellstedt, H. Social Bookmarking                   What's this? Submitted April 29, 2002 Accepted January 23, 2003 T-cell epitopes within the complementarity-determining and framework regions of the tumor derived immunoglobulin heavy chain in multiple myeloma Lotta Hansson, Hodjattallah Rabbani, Jan Fagerberg, Anders Osterborg*, and Hakan Mellstedt Department of Hematology, Karolinska Hospital, Stockholm, Sweden Department of Oncology (Radiumhemmet) and CancerCentreKarolinska, Karolinska Hospital, Stockholm, Sweden * Corresponding author; email: anders.osterborg {at}ks.se. The idiotypic structure of the monoclonal immunoglobulin (Ig) in multiple myeloma (MM) might be regarded a tumor-specific antigen. The present study was designed to identify T-cell epitopes of the variable region of the Ig heavy chain in MM (n=5) using bioinformatics and analyze the presence of naturally occurring T cells against idiotype derived peptides. A large number of HLA-binding (class I and II) peptides were identified. The frequency of predicted epitopes was depended on the database used: 245 in BIMAS and 601 in SYFPEITHI. Most of the peptides displayed a binding-half-life or score in the low or intermediate affinity range. The majority of the predicted peptides were complementarity-determining region (CDR) rather than framework region (FR) derived (52-60% vs. 40-48%). Most of the predicted peptides were confined to the CDR2-FR3-CDR3 geographicalregion of the Ig-VH region (70%) and significantly fewer peptides were found within the flanking (FR1-CDR1-FR2 and FR4) regions (p=<0.01). Eight to ten amino acid (aa) long peptides corresponding to the CDRs and fitting to the actual HLA-A/B haplo-types recognized spontaneously albeit with a low magnitude type I T cells (IFN-) indicating an ongoing MHC class I restricted T-cell response. Most of those peptides had a low binding half-life (BIMAS) and a low/intermediate score (SYFPEITHI). Furthermore, 15-20 aa long CDR 1-3 derived peptides recognized also spontaneously type I T cells indicating the presence of MHC class II restricted T cells as well. This study demonstrates that a large number of HLA-binding idiotypic peptides can be identified in patients with MM. Such peptides may spontaneously induce a type I MHC class I as well as class II restricted memory T cell response. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: S. Cohen, J. Haimovich, and N. Hollander Dendritic Cell-Based Therapeutic Vaccination against Myeloma: Vaccine Formulation Determines Efficacy against Light Chain Myeloma J. Immunol., February 1, 2009; 182(3): 1667 - 1673. [Abstract] [Full Text] [PDF] K. A. Richards, F. A. Chaves, F. R. Krafcik, D. J. Topham, C. A. Lazarski, and A. J. Sant Direct Ex Vivo Analyses of HLA-DR1 Transgenic Mice Reveal an Exceptionally Broad Pattern of Immunodominance in the Primary HLA-DR1-Restricted CD4 T-Cell Response to Influenza Virus Hemagglutinin J. Virol., July 15, 2007; 81(14): 7608 - 7619. [Abstract] [Full Text] [PDF] F. v. Rhee Idiotype Vaccination Strategies in Myeloma: How to Overcome a Dysfunctional Immune System Clin. Cancer Res., March 1, 2007; 13(5): 1353 - 1355. [Full Text] [PDF] L. Hansson, A. O. Abdalla, A. Moshfegh, A. Choudhury, H. Rabbani, B. Nilsson, A. Osterborg, and H. Mellstedt Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients Clin. Cancer Res., March 1, 2007; 13(5): 1503 - 1510. [Abstract] [Full Text] [PDF] A. Bot, D. Smith, B. Phillips, S. Bot, C. Bona, and H. Zaghouani Immunologic Control of Tumors by In Vivo Fc{gamma} Receptor-Targeted Antigen Loading in Conjunction with Double-Stranded RNA-Mediated Immune Modulation J. Immunol., February 1, 2006; 176(3): 1363 - 1374. [Abstract] [Full Text] [PDF] C. Choi, M. Witzens, M. Bucur, M. Feuerer, N. Sommerfeldt, A. Trojan, A. Ho, V. Schirrmacher, H. Goldschmidt, and P. Beckhove Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma Blood, March 1, 2005; 105(5): 2132 - 2134. [Abstract] [Full Text] [PDF] Y.-D. Wang, W.-Y. F. Sin, G.-B. Xu, H.-H. Yang, T.-y. Wong, X.-W. Pang, X.-Y. He, H.-G. Zhang, J. N. L. Ng, C.-S. S. Cheng, et al. T-Cell Epitopes in Severe Acute Respiratory Syndrome (SARS) Coronavirus Spike Protein Elicit a Specific T-Cell Immune Response in Patients Who Recover from SARS J. Virol., June 1, 2004; 78(11): 5612 - 5618. [Abstract] [Full Text] [PDF]

	Copyright © 2003 by American Society of Hematology         Online ISSN: 1528-0020